HKSTP Leads Delegation to Germany and Austria, Forging New Hong Kong–Europe Pathways in New Industrialisation Development

Hong Kong Science and Technology Parks Corporation (HKSTP), in partnership with German Industry and Commerce (GIC) and ADVANTAGE AUSTRIA, and supported by the Innovation, Technology and Industry Bureau, InvestHK and HKETO Berlin, led a delegation of eight Hong Kong Science Park companies to Germany and Austria from 21 to 25 September 2026 for a focused programme of business matching, ecosystem exchange and institutional engagement across Munich, Vienna and Graz. Bringing together government, industry, academia and innovation ecosystem partners, the mission deepened engagement with leading stakeholders, created new opportunities for cross-border collaboration and commercialisation in artificial intelligence (AI), new industralisation, and smart city, and reinforced Hong Kong’s role as a preferred platform for innovation exchange between Europe and Asia.

The high potential tech firms continued the week-long journey in Vienna and Graz, connected with leading Austrian research, industry and innovation organisations.

The high potential tech firms continued the week-long journey in Vienna and Graz, connected with leading Austrian research, industry and innovation organisations.

The delegation marked a major step forward in HKSTP’s growing engagement in Central Europe. As HKSTP’s first market-focused mission to Germany, Europe’s largest AI market and a leading enterprise technology hub, it built on earlier collaboration with ADVANTAGE AUSTRIA, including GO AUSTRIA Spring 2025 and 2026 and the renowned ViennaUP Festival, as well as more recent joint efforts with partners in Germany and Austria under Global Connect and the Global Innovation Exchange. The ongoing efforts created practical pathways for Hong Kong companies to explore partnerships, validate demand and expand into key European markets.

Professor Sun Dong, Secretary for Innovation, Technology and Industry, delivered a speech at the Applied Artificial Intelligence Conference 2026 (AAIC) in Vienna, Austria. He had an exchange with the HKSTP delegation to learn about their innovative solutions.

A key highlight was HKSTP’s participation in the Applied Artificial Intelligence Conference 2026 (AAIC) in Vienna, Austria, to connect with key industry partners and investors for potential business collaboration. Professor Sun Dong, Secretary for Innovation, Technology and Industry, delivered a speech titled “AAIC-Talk: Applied AI in Hong Kong and the Greater Bay Area: Innovation, Industrial Transformation and Opportunities for Collaboration with Austria” at the Austria’s flagship international AI business conference. He shared Hong Kong has elevated AI into a core industry and is emerging as one of the world's most dynamic innovation and technology (I&T) centres. He also invited Austria to partner in shaping AI's next chapter, and highlighting opportunities for collaboration between Hong Kong, the Greater Bay Area and Austria. During the Conference, Professor Sun had a brief exchange with park companies from the delegation participating in the Conference to learn about their innovative solutions.

Professor Sun Dong, Secretary for Innovation, Technology and Industry, delivered a speech at the Applied Artificial Intelligence Conference 2026 (AAIC) in Vienna, Austria. He had an exchange with the HKSTP delegation to learn about their innovative solutions.

Mr Eric Or, Chief Ecosystem Development Officer of HKSTP, said, “HKSTP is committed to helping innovators scale beyond borders. Our inaugural delegation to Germany and the continuous connection with Austria highlights the value of strategic international engagement in opening doors for park companies to connect with leading industry, academic and investors in Europe. It also reflects Hong Kong’s unique role as a gateway for cross-border collaboration, underpinned by its distinct strengths as a super-connector and super value-adder. As HKSTP continues to expand its global outreach to further strengthen Hong Kong’s innovation links with global markets, and reinforce the city’s position as an international innovation and technology hub.”

The delegation began in Munich and visited the Chamber of commerce and industry for Munich and upper Bavaria (IHK).

The delegation began in Munich, focusing on Germany’s industrial AI and enterprise innovation ecosystem, and engaging institutions including Chamber of commerce and industry for Munich and upper Bavaria (IHK), Siemens AI Lab, and the European Union’s top Technical University of Munich (TUM). Discussions centred on industrial AI, advanced manufacturing, technology translation and cross-border collaboration. The high potential tech firms continued the week long journey in Vienna and Graz, connected with leading Austrian research, industry and innovation organisations, including the leading Graz University of Technology (TU Graz), Austrian Institute of Technology and more.

The delegation began in Munich and visited the Chamber of commerce and industry for Munich and upper Bavaria (IHK).

Highlighted innovations from the delegation:

GenAI-Powered Marketing - Amber International Holding Limited introduced MIA, its new agentic AI marketing platform designed to monitor markets, generate on-brand content and support distribution workflows with human approval.

Amber International Holding Limited introduced MIA, its new agentic AI marketing platform designed to monitor markets, generate on-brand content and support distribution workflows with human approval.

Let AI run enterprises. Let AI do business - Echronos AI Group, a China-based innovator in industrial-grade AI Agentic OS, leverages the HKSTP ecosystem and Hong Kong’s global connectivity as a gateway for international expansion. The company introduced its flagship JovaAI platform to European industry leaders. Powered by proprietary semantic and multi-agent orchestration technologies, JovaAI coordinates complex enterprise workflows, from inquiry-to quote orchestration and cross-border customs planning to dynamic production rescheduling.

Echronos AI Group, a China-based innovator in industrial-grade AI Agentic OS, leverages the HKSTP ecosystem and Hong Kong’s global connectivity as a gateway for international expansion.

End-to-end AI Talent Solution - Neufast offers corporate AI strategy consulting and technical implementation for an agentic AI platform covering candidate sourcing, performance appraisals, and leadership development. It is expanding in Europe through partnerships with SAP SuccessFactors for enterprise business transformation and TÜV Rheinland for ISO27001 certification, with the support of the Austrian government’s Go Austria Plus programme by the Global Incubator Network Austria (GIN) and Austrian Research Promotion Agency (FFG).

Neufast offers corporate AI strategy consulting and technical implementation for an agentic AI platform covering candidate sourcing, performance appraisals, and leadership development. It is expanding in Europe through participating in various programmes.

Together, these engagements in Germany and Austria deepened HKSTP’s ties with the regions’ innovation ecosystem and opened new opportunities for collaboration in applied AI, robotics, smart production and commercialisation between Hong Kong and Europe.

Hong Kong Science and Technology Parks Corporation (HKSTP) hosted the HKSTP Cell and Gene Therapy (CGT) Showcase 2026 at the Charles K. Kao Auditorium, Hong Kong Science Park on July 30, with support from Invest Hong Kong. The event brought together more than 200 representatives from the healthcare, academic, investment and regulatory sectors, both locally and from overseas. A major milestone announced at the event was that HKSTP partner company Hong Kong Regen Medtech Limited (HKRM) has become the first facility in Hong Kong to be recognised by the Pharmacy and Poisons Board of Hong Kong (PPBHK) as an allogeneic mesenchymal stem cell (MSC) PIC/S GMP manufacturing facility, enabling the production of advanced therapy products for clinical trials.

HKSTP hosted the HKSTP CGT Showcase 2026, bringing together local and overseas I&T enterprises, medical experts, researchers, investors and patient representatives to explore the clinical translation and broader development of cell and gene therapy. Photo source: HKSTP

Mr. Terry Wong, CEO of HKSTP, said in his remarks: “Cell and gene therapy is one of the fastest-growing fields in life and health tech. The establishment of Hong Kong’s first stem cell production facility certified to PIC/S GMP standards at Hong Kong Science Park marks a significant milestone for the city’s life and health tech ecosystem. The significance of this certification goes far beyond technology alone. It signifies not only that production has met the highest international safety standards, but also that patients and their families can choose locally manufactured cell therapy products with confidence and complete trust. This is a tangible achievement that will enable every Hong Kong citizen to benefit directly. As the orchestrator of Hong Kong’s innovation and technology (I&T) ecosystem, HKSTP has been proactively connecting the life and health tech community with partners, investors and academia. Through a diverse range of incubation programmes, we provide our park companies with seed funding, innovation space, world-class infrastructure and regulatory support, helping them overcome challenges in the journey from laboratory research to clinical translation and turning scientific breakthroughs into real therapeutic outcomes for patients. We will continue to drive ecosystem development and fully support local I&T enterprises in bringing research achievements ‘Made in Hong Kong’ to the global stage.”

In his welcome remarks, HKSTP’s CEO Mr. Terry Wong said that HKSTP, as the orchestrator of Hong Kong’s I&T ecosystem, has been actively connecting the life and health tech community with partners, investors and academia. Through a diverse range of incubation programmes, it supports park companies with seed funding, innovation space, world-class infrastructure and regulatory support, helping them advance from laboratory research to clinical translation and turn scientific breakthroughs into real therapeutic outcomes for patients. Photo source: HKSTP

One of the highlights of the event was HKRM, an HKSTP partner company, recently obtaining Hong Kong’s first PIC/S GMP licence for stem cell production and operating the related manufacturing facility at Hong Kong Science Park, marking a key step in advancing the clinical translation of advanced therapies in Hong Kong. PIC/S GMP is internationally recognised as the gold standard for pharmaceutical manufacturing quality. Facilities must undergo rigorous international assessment to ensure that every batch is produced in a strictly controlled environment.

Mr. Stanley Sy, HKRM Co-founder and CEO, said: “HKRM’s attainment of Hong Kong’s first PIC/S GMP certification for stem cell production marks not only an important milestone in the company’s development, but also signifies that Hong Kong now has the critical infrastructure needed to further support the clinical translation of advanced cell therapies. A stringent, internationally recognised manufacturing quality system helps ensure product consistency and traceability, while strengthening the confidence of medical and regulatory authorities in locally manufactured cell-based products. Based at Hong Kong Science Park, HKRM is grateful for the longstanding support of HKSTP. We also look forward to working with research and clinical partners in the Park to bring more promising therapeutic solutions from Hong Kong to the international stage.”

Mr. Stanley Sy, HKRM Co-founder and CEO, highlighted a major milestone in the development of Hong Kong’s first PIC/S GMP stem cell production facility, underscoring the city’s capabilities in high-quality advanced therapy product manufacturing and clinical translation. Photo source: HKSTP

The event also featured first-hand experiences from patients, their families and doctors on their treatment journeys. Park company Mononuclear Therapeutics (MonoTx) operates Hong Kong’s first AABB-accredited public cord blood bank and haematopoietic stem cell apheresis facility at Hong Kong Science Park, with more than 2,000 cord blood units in storage.

Dr. Wendy Cheng, Chief Operating Officer of MonoTx, introduced Hong Kong’s first AABB-accredited public cord blood bank and haematopoietic stem cell apheresis facility at Hong Kong Science Park, with more than 2,000 cord blood units in storage. Photo source: HKSTP

Dr. Wendy Cheng, Chief Operating Officer of MonoTx, joined Professor Leung Tak Yeung and Professor Ronald Wang of the Department of Obstetrics and Gynaecology at The Chinese University of Hong Kong (CUHK) to share research findings and patient cases with patient families.

Professor Tak Yeung Leung of the Department of Obstetrics and Gynaecology at CUHK (left), together with a patient family (right), shared on stage a research approach for foetuses with severe alpha-thalassaemia, in which the mother’s stem cells are processed by MonoTx and infused into the foetus to investigate whether immune tolerance to the mother’s stem cells can be induced, with the aim of improving clinical outcomes. Photo source: HKSTP

Professor Tak Yeung Leung of the Department of Obstetrics and Gynaecology at CUHK (left), together with a patient family (right), shared on stage a research approach for foetuses with severe alpha-thalassaemia, in which the mother’s stem cells are processed by MonoTx and infused into the foetus to investigate whether immune tolerance to the mother’s stem cells can be induced, with the aim of improving clinical outcomes. Photo source: HKSTP

Professor Leung Tak Yeung’s team at CUHK is studying a treatment for foetuses with severe alpha-thalassaemia by processing the mother’s stem cells through MonoTx and infusing them into the foetus, to investigate whether the foetus can develop immune tolerance to the mother’s stem cells and thereby improve clinical outcomes.

Professor Ronald Wang of CUHK shared his team’s work on using cord blood to treat neonatal brain injury, with preliminary findings suggesting that infusion within 48 hours of birth may help repair brain injury and improve the child’s developmental outcomes later in life. Photo source: HKSTP

Professor Ronald Wang’s team is using cord blood to treat neonatal brain injury. Preliminary findings suggest that cord blood infusion within 48 hours of birth may help repair brain injury and improve the child’s developmental outcomes later in life.

Hong Kong Science Park is home to more than 360 life sciences companies, while the number of cell and gene therapy (CGT) enterprises continues to grow, spanning frontier fields such as stem cells, gene editing, personalised cancer vaccines and CAR-T immunotherapy, and addressing diseases including cancer, heart failure and neurodegenerative disorders.

HKSTP will continue to strengthen Hong Kong’s position as an international health and medical innovation hub by accelerating the translation and application of more locally developed R&D outcomes for the benefit of patients, the industry and society. In doing so, it aims to make innovative therapies more accessible and enable Hong Kong to play an even greater role on the global life and health tech stage.